Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Rule
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Product List March 2019 - Page 1 of 53
Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4 -
The In¯Uence of Medication on Erectile Function
International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted. -
The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone -
Drug Screen Req. 06.2016.Docx Rev 2 Date 06-16 Page 1 of 2
TRUESDAIL LABORATORIES, INC. EXCELLENCE IN INDEPENDENT TESTING Established 1931 3337 MICHELSON DRIVE, SUITE CN 750 IRVINE, CALIFORNIA 92612 (714) 730-6239 FAX (714) 730-6462 www. truesdail.com DRUG SCREEN REQUEST FORM SAMPLE TYPE: Urine Blood Plasma Serum Collection Date: ______________ Doctor: ______________________________ Animal Name, HIP # or Other I.D.:______________________________________ Species: _________ Sex: ________ Owner’s name:_______________________ Pre-Purchase Screening (performed by LC/MS) LEVEL Ι: Includes only nonsteroidal anti-inflammatory drugs (phenylbutazone, $100.00 oxyphenbutazone, flunixin, naproxen, ketoprofen, firocoxib, diclofenac and meclofenamic acid). (Requires a minimum of 2 mL serum or plasma or 10mL of urine) LEVEL ΙΙ: Includes LEVEL Ι drugs plus testing for Domosedan (detomidine), $175.00 fluphenazine, acepromazine, promazine, chlorpromazine, triflupromazine, imipramine, propionylpromazine, clomipramine, and reserpine. (Requires a minimum of 4 mL of serum or plasma or 15mL of urine) LEVEL ΙΙΙ: Includes LEVEL Ι and ΙΙ drugs plus testing for butorphanol, triamcinolone $250.00 acetonide, betamethasone, dexamethasone, flumethasone, isoflupredone, predisone, methylprednisolone, prednisolone, albuterol, clenbuterol, terbutaline, and pirbuterol. (Requires a minimum of 5 mL of serum or plasma or 20mL of urine) LEVEL ΙV: TOBA Protocol Testing (urine and blood is required for this test) $300.00 (Requires a minimum of 6 mL of serum or plasma and 25mL of urine) *Rush testing is available for Level I, II or III -
Crystal Structure of Dopamine D1 Receptor in Complex with G Protein and a Non-Catechol Agonist
ARTICLE https://doi.org/10.1038/s41467-021-23519-9 OPEN Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist Bingfa Sun 1,7, Dan Feng1,7, Matthew Ling-Hon Chu1, Inbar Fish1, Silvia Lovera2, Zara A. Sands2,6, Sebastian Kelm 3, Anne Valade2, Martyn Wood2, Tom Ceska 3, Tong Sun Kobilka1, Florence Lebon4 & ✉ Brian K. Kobilka 1,5 Dopamine D1 receptor (D1R) is an important drug target implicated in many psychiatric and 1234567890():,; neurological disorders. Selective agonism of D1R are sought to be the therapeutic strategy for these disorders. Most selective D1R agonists share a dopamine-like catechol moiety in their molecular structure, and their therapeutic potential is therefore limited by poor pharmaco- logical properties in vivo. Recently, a class of non-catechol D1R selective agonists with a distinct scaffold and pharmacological properties were reported. Here, we report the crystal structure of D1R in complex with stimulatory G protein (Gs) and a non-catechol agonist Compound 1 at 3.8 Å resolution. The structure reveals the ligand bound to D1R in an extended conformation, spanning from the orthosteric site to extracellular loop 2 (ECL2). Structural analysis reveals that the unique features of D1R ligand binding pocket explains the remarkable selectivity of this scaffold for D1R over other aminergic receptors, and sheds light on the mechanism for D1R activation by the non-catechol agonist. 1 ConfometRx, Inc., Santa Clara, CA, USA. 2 UCB Pharma, Braine-l’Alleud, Belgium. 3 UCB Pharma, Slough, UK. 4 UCB Pharma, Anderlecht, Belgium. 5 Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. -
Prohibited Substances List
Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). -
Detomidine and Butorphanol for Standing Sedation in a Range of Zoo-Kept Ungulate Species
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Ghent University Academic Bibliography Journal of Zoo and Wildlife Medicine 48(3): 616–626, 2017 Copyright 2017 by American Association of Zoo Veterinarians DETOMIDINE AND BUTORPHANOL FOR STANDING SEDATION IN A RANGE OF ZOO-KEPT UNGULATE SPECIES Tim Bouts, D.V.M., M.Sc., Dip. E.C.Z.M., Joanne Dodds, V.N., Karla Berry, V.N., Abdi Arif, M.V.Sc., Polly Taylor, Vet. M. B., Ph. D., Dip. E.C.V.A.A., Andrew Routh, B. V. Sc., Cert. Zoo. Med., and Frank Gasthuys, D.V.M., Ph. D., Dip. E.C.V.A.A. Abstract: General anesthesia poses risks for larger zoo species, like cardiorespiratory depression, myopathy, and hyperthermia. In ruminants, ruminal bloat and regurgitation of rumen contents with potential aspiration pneumonia are added risks. Thus, the use of sedation to perform minor procedures is justified in zoo animals. A combination of detomidine and butorphanol has been routinely used in domestic animals. This drug combination, administered by remote intramuscular injection, can also be applied for standing sedation in a range of zoo animals, allowing a number of minor procedures. The combination was successfully administered in five species of nondomesticated equids (Przewalski horse [Equus ferus przewalskii; n ¼ 1], onager [Equus hemionus onager; n ¼ 4], kiang [Equus kiang; n ¼ 3], Grevy’s zebra [Equus grevyi; n ¼ 4], and Somali wild ass [Equus africanus somaliensis; n ¼ 7]), with a mean dose range of 0.10–0.17 mg/kg detomidine and 0.07–0.13 mg/kg butorphanol; the white (Ceratotherium simum simum; n ¼ 12) and greater one-horned rhinoceros (Rhinoceros unicornis; n ¼ 4), with a mean dose of 0.015 mg/kg of both detomidine and butorphanol; and Asiatic elephant bulls (Elephas maximus; n ¼ 2), with a mean dose of 0.018 mg/kg of both detomidine and butorphanol. -
PRACTITIONER's GUIDE Perfect for Routine Procedures on Horses That DON't Want to Have Anything to DO with Routine Procedure
DORMOSEDAN GEL is a registered trademark of Orion Corporation and is distributed by Pfizer Inc. ©2010 Pfizer Inc. All rights reserved. DOR0710058 iMpORtANt SAfEty iNfORMAtiON DORMOSEDAN GEL® is contraindicated in horses with known hypersensitivity to detomidine. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses, as potentially fatal dysrhythmias may occur. Do not use DORMOSEDAN GEL in horses with pre-existing atrio-ventricular (AV) or sino-atrial (SA) blocks, cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation or stress due to extreme heat, cold, fatigue or high altitude. Appropriate precautions should be taken while handling and using gel dosing syringes, as DORMOSEDAN GEL can be absorbed following direct exposure to skin, eyes or mouth, and may cause irritation. The use of impermeable gloves is advised. Please see the full prescribing information, or go to www.DormosedanGel.com. www.DormosedanGel.com PerfEct for routine procedures on horses hERE’S hOw DORMOSEDAN GEL wORkS: DORMOSEDAN GEL cAN bE ADMiNiStERED by yOuR thAt don’t want tO hAvE anything tO do cLiENtS fOR A wiDE vARiEty Of routiNE procEDuRES. Detomidine is a potent and relatively selective α2-adrenoceptor agonist with a with routine procedures. central effect inhibiting the transmission of norepinephrine-mediated nervous Depending on the horse’s specific needs, DORMOSEDAN GEL® is impulses. In the animal, the level of consciousness is lowered. The well-characterized an effective standing sedation for use prior to stressful situations profile of detomidine at the receptor level explains its predictable, dose-dependent and minor, nonpainful husbandry procedures, including: pharmacological effects. -
The Effect of Dexmedetomidine and Clonidine on the Inflammatory Response in Critical Illness: a Systematic Review of Animal and Human Studies Charles A
Flanders et al. Critical Care (2019) 23:402 https://doi.org/10.1186/s13054-019-2690-4 RESEARCH Open Access The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies Charles A. Flanders1† , Alistair S. Rocke1†, Stuart A. Edwardson2, J. Kenneth Baillie1 and Timothy S. Walsh1,2,3* Abstract Background: The α2 agonists, dexmedetomidine and clonidine, are used as sedative drugs during critical illness. These drugs may have anti-inflammatory effects, which might be relevant to critical illness, but a systematic review of published literature has not been published. We reviewed animal and human studies relevant to critical illness to summarise the evidence for an anti-inflammatory effect from α2 agonists. Methods: We searched PubMed, the Cochrane library, and Medline. Animal and human studies published in English were included. Broad search terms were used: dexmedetomidine or clonidine, sepsis, and inflammation. Reference lists were screened for additional publications. Titles and abstracts were screened independently by two reviewers and full-text articles obtained for potentially eligible studies. Data extraction used a bespoke template given study diversity, and quality assessment was qualitative. Results: Study diversity meant meta-analysis was not feasible so descriptive synthesis was undertaken. We identified 30 animal studies (caecal ligation/puncture (9), lipopolysaccharide (14), acute lung injury (5), and ischaemia-reperfusion syndrome (5)), and 9 human studies. Most animal (26 dexmedetomidine, 4 clonidine) and all human studies used dexmedetomidine. In animal studies, α2 agonists reduced serum and/or tissue TNFα (20 studies), IL-6 (17 studies), IL-1β (7 studies), NFκB (6 studies), TLR4 (6 studies), and a range of other mediators. -
National Clearinghouse for Drug Abuse Information Selected Reference Series, Series 1, No
DOCUMENT RESOHE ED 090 455 CG 008 832 TITLE National Clearinghouse For Drug Abuse Information Selected Reference Series, Series 1, No. 1. INSTITUTION National Inst. of Mental Health (DHEW), Rockville, Hd. National Clearinghouse for Drug Abuse Information.; Student Association for the Study of Hallucinogens, Biloit, His. PDB DATE Nov 73 NOTE 13p. AVAILABLE FROM National Clearinghouse for Drug Abuse Information, p. 0. Box 1908, Rockville, Maryland 20850 EDRS PRICE MF-10.75 HC-S1.50 PLUS POSTAGE DESCRIPTORS ^Bibliographies; *Drug Abuse; *Drug Education; *Drug Therapy; Government Publications; ^Narcotics ABSTRACT One of a series of bibliographies published by the National Clearinghouse for Drug Abuse Information, this reference focuses on the drug, methagualone. Literature is selected for inclusion on the basis of its currency, significance in the field, and its availability to the public. Materials are directed toward researchers, educators, lawyers, physicians, and members of the public with more than a general need for information. Citations are not annotated. (Author/CJ) SERIES 7, No.l NOVEMBER 1973 Each bibliography of the National Clearinghouse for Drug Abuse 3- Information Selected Reference Series is a representative listing of citations on subjects of topical interest. The selection of o literature is based on its currency, its significance in the field, and its availability in local bookstores or research libraries. The scope of the material is directed toward students writing research papers, special interest groups, such as educators, lawyers and phy sicians, and the general public requiring more resources than public information materials can provide. Each reference series is meant to present an overview of the existing literature, but is not meant to be comprehensive or definitive in scope. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
The Use of Central Nervous System Active Drugs During Pregnancy
Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.